Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report

Area of Science:

• Gynecology
• Oncology
• Biochemistry

Background:

• Urine beta-core fragment, also known as beta-core/UGF/UGP, has been investigated as a potential biomarker for gynecological cancers since 1988.
• Three commercial immunoassays are currently available for its detection.

Purpose of the Study:

• To compare three commercial immunoassays for urine beta-core/UGF/UGP.
• To establish cutoff limits for the marker.
• To evaluate the marker's sensitivity and specificity in retrospective and prospective studies of gynecological cancer patients.

Main Methods:

• A retrospective study analyzed 486 urine samples from gynecological cancer patients and controls.
• A prospective study monitored 548 new patients at a Gynecology Oncology Clinic over 16 months.
• The Ciba-Corning kit was used to measure beta-core/UGF/UGP levels in all samples.

Main Results:

• Elevated beta-core/UGF/UGP levels (>1.9 ng/ml) were found in 11% of healthy individuals and 11% with benign gynecological disease.
• In retrospective and prospective studies, elevated levels were detected in 50% and 48% of gynecological cancer samples, respectively.
• Sensitivity increased with advancing cancer stage, ranging from 28-29% for stage I to 68-77% for stage IV.

Conclusions:

• Urine beta-core/UGF/UGP demonstrates potential as a general, stage-dependent tumor marker for gynecological cancers.
• The marker's sensitivity is higher for advanced-stage malignancies.
• Findings from both retrospective and prospective studies confirm its utility and suggest a definitive false-positive rate and sensitivity.